Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.48 |
| ▸ | RIPK1 | Q13546 | 4/20 | 0.48 |
| ▸ | JAK2 | O60674 | 7/20 | 0.44 |
| ▸ | NTRK1 | P04629 | 7/20 | 0.44 |
| ▸ | SCD | O00767 | 1/20 | 0.41 |
| ▸ | PDE5A | O76074 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.39 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4032833 | 0.83 | RIPK1 (0.64) | PIK3CDRIPK1SCD | |
| SCHEMBL18863621 | 0.83 | RIPK1 (0.64) | PIK3CDRIPK1SCD | |
| SCHEMBL4070782 | 0.83 | RIPK1 (0.64) | PIK3CDRIPK1SCD | |
| SCHEMBL433245 | 0.81 | RIPK1 (0.51) | PIK3CDRIPK1JAK2NTRK1PDE5A | |
| SCHEMBL29429632 | 0.81 | RIPK1 (0.51) | PIK3CDRIPK1JAK2NTRK1PDE5A | |
| SCHEMBL448616 | 0.81 | RIPK1 (0.51) | PIK3CDRIPK1JAK2NTRK1PDE5A | |
| SCHEMBL430769 | 0.81 | RIPK1 (0.51) | PIK3CDRIPK1JAK2NTRK1PDE5A | |
| SCHEMBL448615 | 0.81 | RIPK1 (0.51) | PIK3CDRIPK1JAK2NTRK1PDE5A | |
| SCHEMBL18555831 | 0.79 | RIPK1 (0.39) | PIK3CDRIPK1JAK2NTRK1SCD | |
| SCHEMBL18555495 | 0.79 | RIPK1 (0.39) | PIK3CDRIPK1JAK2NTRK1SCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240132500-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS | ARRAY BIOPHARMA INC (US) | 2024-04-25 | — | — | US | disclosed |
| US-20230234955-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS | ARRAY BIOPHARMA INC (US) | 2023-07-27 | — | — | US | disclosed |
| EP-3372605-B1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2021-11-03 | — | — | EP | disclosed |
| US-20210002287-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS | ARRAY BIOPHARMA INC. | 2021-01-07 | — | — | US | disclosed |
| US-10774085-B2 | Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds | ARRAY BIOPHARMA INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20190211017-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS | ARRAY BIOPHARMA INC. | 2019-07-11 | — | — | US | disclosed |
| EP-3372605-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2018-09-12 | — | — | EP | disclosed |
| US-10005783-B2 | Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds | ARRAY BIOPHARMA INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-20180127427-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS | ARRAY BIOPHARMA INC. | 2018-05-10 | — | — | US | disclosed |
| US-9676783-B2 | Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds | ARRAY BIOPHARMA, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| EP-2725028-B1 | Substituted pyrazolo[1,5-]pyrimidine compounds as intermediates in the synthesis of TRK kinase inhibitors | ARRAY BIOPHARMA INC (US) | 2016-05-25 | — | — | EP | disclosed |
| US-9127013-B2 | Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds | ARRAY BIOPHARMA, INC. (US) | 2015-09-08 | — | — | US | disclosed |
| US-20150133429-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-a] PYRIMIDINE COMPOUNDS | ARRAY BIOPHARMA, INC. | 2015-05-14 | — | — | US | disclosed |
| US-20150005499-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS | ARRAY BIOPHARMA, INC. | 2015-01-01 | — | — | US | disclosed |
| US-8865698-B2 | Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds | ARRAY BIOPHARMA INC. (US) | 2014-10-21 | — | — | US | disclosed |
| US-20140194403-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS | ARRAY BIOPHARMA INC. (US) | 2014-07-10 | — | — | US | disclosed |
| EP-2725028-A1 | Substituted pyrazolo[1,5-]pyrimidine compounds as intermediates in the synthesis of TRK kinase inhibitors | Array Biopharma, Inc. (US) | 2014-04-30 | — | — | EP | disclosed |
| EP-2350071-B1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2014-01-08 | — | — | EP | disclosed |
| US-8513263-B2 | Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-20110195948-A1 | Substituted Pyrazolo[1,5-a]Pyrimidine Compounds as TRK Kinase Inhibitors | ARRAY BIOPHARMA INC. (US) | 2011-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132500-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS | TYMP, TYMS, P2RX7 | PIK3CD 2967/4885RIPK1 3656/4885JAK2 1199/4885 |
| US-20110195948-A1 | Substituted Pyrazolo[1,5-a]Pyrimidine Compounds as TRK Kinase Inhibitors | PDXK, DTYMK, TNNI3K | PIK3CD 538/4885RIPK1 321/4885JAK2 186/4885 |
| US-20180127427-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS | TYMP, TYMS, P2RX7 | PIK3CD 2967/4885RIPK1 3656/4885JAK2 1199/4885 |
| US-20190211017-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS | TYMP, TYMS, P2RX7 | PIK3CD 2967/4885RIPK1 3656/4885JAK2 1199/4885 |
| US-10005783-B2 | Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds | TYMP, TYMS, P2RX7 | PIK3CD 2967/4885RIPK1 3656/4885JAK2 1199/4885 |
| US-20230234955-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS | TYMP, TYMS, TK1 | PIK3CD 2424/4885RIPK1 3419/4885JAK2 1795/4885 |
| US-10774085-B2 | Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds | TYMP, TYMS, P2RX7 | PIK3CD 2967/4885RIPK1 3656/4885JAK2 1199/4885 |
| US-20150133429-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-a] PYRIMIDINE COMPOUNDS | TYMP, TYMS, P2RX7 | PIK3CD 2967/4885RIPK1 3656/4885JAK2 1199/4885 |
| US-20210002287-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS | TYMP, TYMS, P2RX7 | PIK3CD 2967/4885RIPK1 3656/4885JAK2 1199/4885 |
| US-20140194403-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS | P2RX7, P2RX1, P2RX3 | PIK3CD 4041/4885RIPK1 4415/4885JAK2 372/4885 |
| US-20150005499-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS | TYMP, TYMS, P2RX7 | PIK3CD 2967/4885RIPK1 3656/4885JAK2 1199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.